Skip to main content

Quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells (EMEA)

 Guideline on quality, non-clinical, and clinical aspects of medicinal products containing genetically modified cells" is a regulatory or guidance document issued by a health authority or regulatory agency. This guideline provides comprehensive guidance and requirements for the development, evaluation, and approval of medicinal products that contain genetically modified cells. Here's an overview of the key aspects typically covered in such a guideline:


1. Introduction:

The document likely begins with an introduction, explaining the purpose and scope of the guideline. It may also provide background information on the use of genetically modified cells in medicinal products.

2. Quality Aspects:

Quality considerations are a critical part of any medicinal product development. The guideline may provide detailed requirements for the quality control and assurance of genetically modified cells, including:

  • Characterization of the genetically modified cells.
  • Manufacturing processes, including cell culture, genetic modification, and downstream processing.
  • Testing methods for assessing the identity, potency, purity, and safety of the cells.
  • Control of raw materials and reagents used in cell production.
  • Stability testing to determine the shelf life and storage conditions of the product.

3. Non-Clinical Aspects:

  • The non-clinical section of the guideline would focus on preclinical studies and data requirements. This may include:
  • In vitro and in vivo studies to evaluate the safety, efficacy, and biodistribution of the genetically modified cells.
  • Assessment of potential toxicities and immune responses.
  • Consideration of off-target effects of genetic modifications.
  • Data on the persistence and fate of the modified cells in animal models.

4. Clinical Aspects:

This section addresses clinical trials involving genetically modified cells, including:

  • Requirements for designing and conducting clinical trials, including Phase I, II, and III studies.
  • Informed consent and ethical considerations.
  • Patient eligibility criteria and patient monitoring during trials.
  • Data collection and analysis for safety and efficacy.
  • Reporting of adverse events and serious adverse events.
  • Long-term follow-up of patients to assess the durability of therapeutic effects and potential long-term risks.

5. Regulatory Considerations:

The document may outline the regulatory pathways and requirements for the approval of medicinal products containing genetically modified cells. This includes interactions with regulatory agencies, submission of regulatory documents, and compliance with regulatory standards.

6. Risk Management and Pharmacovigilance:

Guidelines often include recommendations for risk management plans and pharmacovigilance activities to monitor the safety of these products after they are on the market.

7. Post-Market Surveillance:

There may be recommendations for post-market surveillance and data collection to assess the long-term safety and efficacy of these products in real-world settings.

8. References and Appendices:

The document includes references to relevant scientific literature and may include appendices with additional details or forms for regulatory submissions.

https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-clinical-aspects-medicinal-products-containing-genetically-modified_en-0.pdf


Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

Overview of Cut Point Calculation in the Presence of Pre-existing Antibodies

The process involves statistical methods that account for variations in baseline ADA levels across the study population. Here’s a structured approach to calculate the cut point when there is a pre-existing antibody response: 1. Collect Baseline ADA Samples Sample Population : Collect samples from a representative population of treatment-naïve subjects (typically 50-100 individuals). These baseline samples should reflect the typical range of pre-existing ADA levels within the target patient population. Matrix Type : Use serum or plasma samples, as appropriate for the assay matrix. Time Points : Ideally, collect multiple samples per subject pre-treatment to get a clear baseline. 2. Run Baseline Samples in ADA Assay Perform the ADA assay on all baseline samples, running each sample in triplicate to account for intra-assay variability. Record the response values (e.g., optical density (OD) in ELISA) for each sample. If using multiple replicates, calculate the mean response for each sample....
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more